Role of Photodynamic Therapy in the Palliation of Obstructing Esophageal Cancer

Yoon, Hun‐Young; Cheon, Young Koog; Choi, Hye Jin; Shim, Chan Sup

doi:10.3904/kjim.2012.27.3.278

Cited by 33 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Photodynamic therapy (PDT) is a novel oncotherapy exerting a selective cytotoxic activity toward malignant cells via reactive oxygen species (ROS) generated by energy transduction from photosensitizers after excitation by visible light. Photofrin was the first photosensitizer approved by FDA in 1995 and Photofrin‐mediated PDT is the most widely used for reducing obstruction and relieving symptoms in patients with obstructing esophageal cancer . In spite of promising initial treatment responses after PDT, 5‐year recurrence rate remains at high level .…”

Section: Introductionmentioning

confidence: 99%

Enhanced phototoxicity of photodynamic treatment by Cx26‐composed GJIC via ROS‐, calcium‐ and lipid peroxide‐mediated pathways

Lin

Bai

et al. 2017

Journal of Biophotonics

View full text Add to dashboard Cite

In spite of the promising initial treatment responses presented by photodynamic therapy (PDT), 5-year recurrence rates remain high level. Therefore, improvement in the efficacy of PDT is needed. There are reports showing that connexin(Cx) 26-composed gap junctional intercellular communication (GJIC) enhances the intercellular propagation of "death signal", thereby increasing chemotherapeutic cytotoxicity. However, it is unclear whether Cx26-formed GJIC has an effect on PDT phototoxicity. The results in the present study showed that Cx26-composed GJ formation at high density enhances the phototoxicity of Photofrin-PDT. When the Cx26 is not expressed or Cx26 channels are blocked, the phototoxicity in high-density cultures substantially reduces, indicating that the enhanced PDT phototoxicity at high density is mediated by Cx26-composed GJIC. The GJIC-mediated increase in PDT phototoxicity was associated with ROS, calcium and lipid peroxide-mediated stress signaling pathways. The work presents the ability of Cx26-composed GJIC to enhance the sensitivity of malignant cells to PDT, and indicates that maintenance or increase of Cx26-formed GJIC may be a profitable strategy towards the enhancement of PDT therapeutic efficiency.Picture: The survival response of Photofrin-PDT in Doxtreated (Cx26 expressing, GJ-formed) and Dox-untreated cells (Cx26 non-expressing, GJ-unformed) at high-cell density condition.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhanced phototoxicity of photodynamic treatment by Cx26‐composed GJIC via ROS‐, calcium‐ and lipid peroxide‐mediated pathways

Lin

Bai

et al. 2017

Journal of Biophotonics

View full text Add to dashboard Cite

show abstract

“…This technique has resulted in regression and, in some cases, complete reversal of BE [7-10]. Since then, some studies of patients with esophageal dysplasia and cancer have reported that complete remission (CR) can be achieved in superficial lesions using PDT (Table 1) [11-19]. Studies on the use of PDT for esophageal squamous cell carcinoma (SCC) confined to the mucosal layer have suggested that PDT can be used as an alternative to esophagectomy given the low risk of lymph node metastasis in these patients.…”

Section: Esophageal Cancermentioning

confidence: 99%

Application of photodynamic therapy in gastrointestinal disorders: an outdated or re-emerging technique?

Lee

Choi

Hasan

2017

Korean J Intern Med

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a promising therapeutic modality that involves the administration of a photosensitizer followed by local illumination with a specific wavelength of light in the presence of oxygen. PDT is minimally invasive, has high selectivity for cancer, and has good patient compliance due to the simplicity of the procedure; therefore, PDT is widely used as a palliative and salvage treatment in patients with various gastrointestinal malignancies. When used as a salvage treatment for locoregional failures after definitive chemoradiotherapy for esophageal cancer, favorable results have been reported. PDT in conjunction with biliary stenting is a promising palliative treatment for unresectable cholangiocarcinoma, and can be used as an advanced diagnostic and therapeutic strategy in peritoneal dissemination of gastric cancer. Recent clinical reports of PDT for treating non-resectable pancreatic cancer also show promising results. To widen the application of PDT, the integration of PDT with molecular imaging and nanotechnology is being extensively studied. Based on these new developments, PDT is likely to re-emerge as a valuable technique in the treatment of diverse gastrointestinal diseases.

show abstract

“…Несмотря на появление новых методов диагностики и лечения рака пищевода на ранних стадиях в последние годы, частота выявления больных с РП на III-IV стадиях заболевания по-прежнему остается очень высокой и составляет более 67% [2]. Важным показателем злокачественности течения рака пищевода являются низкие показатели 5-летней выживаемости, не превышающие 10-15% как в России, так и в странах Европы [3]. В половине случаев основным клиническим симптомом рака пищевода является дисфагия, возникающая при сужении просвета на 50-70% [4], когда возможности хирургического, лучевого, комбинированного и комплексного лечения ограничены [1,2,5].…”

Section: Introductionunclassified

Experience of using photodynamic therapy in the treatment of esophageal cancer

Туманина

Полежаев²,

Апанасевич³

et al. 2019

Biomedical photonics

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a worthy alternative to surgical esophageal resection or endoscopic mucosal resection and dissection (EMR, ESD) in patients with superficial esophageal cancer with severe concomitant diseases as well as in patients with a common form of esophageal cancer with severe malignant dysphagia. Patients with superficial (7) and advanced (15) esophageal cancer received PDT as an independent method and as a supplement to complex treatment. Radachlorin was used as a photosensitizer at a dose of 0.6–0.8 mg/kg, administered intravenously 3 hours before irradiation. A PDT session was carried out using a laser with a wavelength of 662 nm. The light dose used was 150–300 J/cm2 . The use of PDT made it possible to achieve the full effect in 7 (100%) patients in the group of superficial (T1a-T1b) esophageal cancer where PDT was either the only method of treatment or in combination with radiation therapy. In the group of patients with stenotic cancer the use of PDT made it possible to achieve full recovery of food intake after recanalization for 20% of patients, and partial – for 66.7%. Thus, complete natural food intake was restored for 86.7% of patients which improved their quality of life. PDT is also a method of choice for cancer of the upper esophagus as esophageal stenting in this situation can cause unwanted subjective sensations.

show abstract

Role of Photodynamic Therapy in the Palliation of Obstructing Esophageal Cancer

Cited by 33 publications

References 20 publications

Enhanced phototoxicity of photodynamic treatment by Cx26‐composed GJIC via ROS‐, calcium‐ and lipid peroxide‐mediated pathways

Enhanced phototoxicity of photodynamic treatment by Cx26‐composed GJIC via ROS‐, calcium‐ and lipid peroxide‐mediated pathways

Application of photodynamic therapy in gastrointestinal disorders: an outdated or re-emerging technique?

Experience of using photodynamic therapy in the treatment of esophageal cancer

Contact Info

Product

Resources

About